Neurology Central

Case report highlights potential of repurposed drug for Alzheimer’s disease treatment

A small study carried out at the Human Microbiology Institute (NY, USA) and published recently in the Journal of Medical Case Reports, has revealed a potential new treatment for late-stage Alzheimer’s disease.

A team made up of Victor Tetz and George Tetz  (both Human Microbiology Institute) treated a 77 year old Alzheimer’s patient with deoxyribonuclease I, a repurposed medication previously approved by the FDA for the treatment of mucus buildup in cystic fibrosis patients.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.